摘要
Objectives: Transformed small-cell lung cancer (T-SCLC) has an extremely poor prognosis, and no remedies based on immunotherapy have been evaluated among T-SCLC patients. We retrospectively analysed the efficacy and safety of combining atezolizumab with chemotherapy for T-SCLC.Methods: Forty-seven patients harbouring EGFR mutations who developed T-SCLC were enrolled. Eleven patients who used immunotherapy were defined as the I/O group, and the remaining 36 were defined as the Non-I/O group. Clinical characteristics, pathological data, and survival outcomes were collected. RNA sequencing and whole-exome sequencing (WES) were performed for in-depth analysis.Results: All patients received at least one line of EGFR-TKI before rebiopsy to confirm T-SCLC. Nine patients received atezolizumab-bevacizumab-carboplatin-paclitaxel (albumin-bound) (ABCP), and the remaining 2 received atezolizumab-etoposide-carboplatin (ECT) in the I/O group. The objective response rate was 73 % (8/ 11). The median progression-free survival (mPFS) of T-SCLC on post-transformation therapy with I/O group and Non-I/O group was 5.1 m and 4.1 m, respectively. The median post-T-SCLC overall survival of the I/O group was significantly longer than that Non-I/O group (20.2 m vs 7.9 m, P < 0.01). T-SCLC harbouring EGFR L858R tended to be longer than EGFR 19del (mPFS: not reached vs 3.7 m, P = 0.11). Positive PD-L1 status was also associated with PFS benefits (mPFS: 6.0 m vs 3.7 m, P = 0.20). Furthermore, RNA sequencing revealed that expression of SFTPA1 is significantly higher in the durable clinical benefit group. WES showed that STC2 mu-tation is more frequently observed at the time-point immunotherapy acquired resistance. Combination therapy based on a PD-L1 inhibitor was well tolerated, and the safety profile was consistent with previously reported studies.Conclusion: Our study first demonstrated that a PD-L1 inhibitor combined with chemotherapy & PLUSMN; bevacizumab could be a potential safe option for specific SCLC-transformed patients. Subsequent studies with more patients are essential to verify the efficacy and potential biomarkers.
学科与关键词
- Expression of EGFR-mutant proteins and genomic evolution in EGFR-mutant transformed small cell lung cancerZhang, Shi-Ling; Zhang, Chan -Yuan; Chen, Yu-Qing; Li, Yu -Fa; Xie, Zhi; Zhang, Xu-Chao; Zhou, Qing; Zhong, Wen-Zhao; Huang, Jie; Sun, Hao; Zheng, Ming-Ying; Xiao, Fa-Man; Yan, Hong-Hong; Lu, Dan-Xia; Lv, Zhi-Yi; Wu, Yi-Long; Chen, Hua-Jun*; Yang, Jin-Ji*Journal of Thoracic Disease, 2023, 15(9).
- Chemotherapy plus EGFR TKIs or Bevacizumab versus Chemotherapy Alone in SCLC-Transformed EGFR-Mutant Lung AdenocarcinomaZhang, C.; Zhang, S.; Yao, Y.; Gao, Y.; Huang, J.; Peng, K.; Gao, Q.; Chen, H.; Xu, C.; Zhang, X.; Wu, Y.; Yang, J.被引 3
- Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case reportXue, Lei; Chen, Baishen; Lin, Junshuang; Peng, Jiangzhou*Annals of Palliative Medicine, 2021, 10(1): 828-835.被引 2
